Anthem (NASDAQ:ANTX) Shares Cross Above Two Hundred Day Moving Average - What's Next?

Key Points

• ANTX shares rose 17.1% and traded as high as $4.60, moving above the 200-day average of $4.00. The stock later traded near $4.52 on volume of approximately 545,190 shares.
• Analyst sentiment remains mixed, with two Buy ratings and one Sell rating producing an overall Hold consensus and a $9.00 average price target.
• The company reported a quarterly loss of $0.18 per share, while insiders sold 52,901 shares worth about $318,282 over the past 90 days. Institutional investors own approximately 90.47% of the stock.

Anthem, Inc. (NASDAQ:ANTX - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.00 and traded as high as $4.60. Anthem shares last traded at $4.52, with a volume of 545,190 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts recently commented on ANTX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Anthem in a report on Friday, October 2nd. Guggenheim started coverage on shares of Anthem in a report on Monday, July 20th. They set a "buy" rating and a $9.00 target price for the company. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $9.00.

Anthem Stock Up 17.1%

The firm's 50-day moving average price is $4.95 and its two-hundred day moving average price is $4.00. The firm has a market capitalization of $170.57 million, a PE ratio of -4.22 and a beta of -0.98.

Anthem (NASDAQ:ANTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter.

Insider Activity at Anthem

In other news, Director Robin Shane Readnour sold 10,019 shares of Anthem stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $6.02, for a total transaction of $60,314.38. Following the transaction, the director owned 557,990 shares in the company, valued at approximately $3,359,099.80. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 52,901 shares of company stock valued at $318,282 over the last ninety days. Company insiders own 22.61% of the company's stock.

Institutional Investors Weigh In On Anthem

Several hedge funds have recently bought and sold shares of the business. Citizens Financial Group Inc. RI acquired a new position in shares of Anthem during the 2nd quarter worth $1,443,000. ADAR1 Capital Management LLC acquired a new stake in shares of Anthem in the 1st quarter valued at $47,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Anthem in the 1st quarter valued at $54,000. Velan Capital Investment Management LP acquired a new stake in shares of Anthem in the 2nd quarter valued at $194,000. Finally, Seven Fleet Capital Management LP bought a new stake in Anthem in the first quarter worth $683,000. 90.47% of the stock is owned by hedge funds and other institutional investors.

Anthem Company Profile

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.